How biotechs can strengthen their value story with advanced analytics

Small and emerging companies must make big decisions about what to do with their assets early in development. Should they seek venture capital (VC) funding to develop a product themselves or seek a partner once it shows clinical activity? They need to know their product candidate’s value and commercial viability to make the right decision, including the market size, growth and revenue potential.

Recent advances in machine learning and predictive analytics have empowered health economics and outcomes research (HEOR). Sophisticated tools are now available to help build a data-driven value story that can help attract investors and partners, convince payers, and benefit patients. Here are five ways biotech companies can enhance their value story with advanced analytics.

Open PDF

Return to Insights Center

Related Insights


Are you using real-world evidence?

Feb 1, 2023


Addressing the Challenges of Artificial Intelligence used for Data Extraction in Systematic Literature Reviews

Mar 15, 2023


Use of AI to develop health economic evidence for optimized patient access

Sep 6, 2023


Three strategies for articulating a coherent product value story

Dec 18, 2021


Successful decentralized clinical trial (DCT) approaches

May 28, 2023


Pharma Talk Radio: Building a Successful Relationship with your Development Partner

Oct 5, 2021


Actigraphy advances a patient-first approach: Reduce patient burden — and make the most of valuable data

Oct 15, 2021


Expedited Pathways Comparisons - US EU CHN

Oct 19, 2021


Overcoming asset transfer challenges during a merger and acquisition (M&A)

Oct 20, 2021


Clinical pharmacology, modeling and simulation to support FIH study design

Oct 21, 2021


CNS Summit Recap: The Future is Collaborative

Nov 22, 2021


Studying multiple versions of a cellular or gene therapy product in an early-phase clinical trial

Nov 19, 2021